Login to Your Account

GenVec Stands to Gain $213M in Novartis Hearing Loss Pact

By Donna Young

Wednesday, January 20, 2010
As big pharma continues its trend of targeting biotech-discovered technology to fill the mega-drugmakers' depleting pipelines - with preclinical work becoming even more frequently eyed within that scope - Swiss manufacturer Novartis AG is the latest to take aim, inking a deal with GenVec Inc. potentially worth more than $213.6 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription